Skip to content

Healthy Moms, Healthy Babies

Healthy Moms, Healthy Babies: A Strategy to Improve the Care and OUtcome of Diabetes in Pregnancy in On-Reserve First Nations Women

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01578460
Acronym
HMHB
Enrollment
18
Registered
2012-04-17
Start date
2012-05-31
Completion date
2014-08-29
Last updated
2017-03-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gestational Diabetes, Type 2 Diabetes Mellitus

Keywords

Pregnancy, Gestational Diabetes, Type 2 Diabetes Mellitus, Continuous Glucose Monitor, Glucose

Brief summary

Poor glucose control during pregnancy is a significant concern for Canadian women with diabetes. This problem is magnified in First Nations women, who have among the highest rates of gestational diabetes (GDM) in the world (up to 18% of First Nations women will develop GDM during pregnancy and 70% of these will go on to develop type 2 diabetes later). Continuous glucose monitoring (CGM) technology has the potential to help women maintain tighter control during pregnancy, however, in the First Nations population, there are many unique barriers that may affect use of this technology. Such barriers include remoteness of the community, cultural apprehension, lack or difficulty of access to care, and language differences. A total of 60 participants from three participating First Nations communities in Southern Ontario will participate in the study. Participants will self-select to either the CGM group (n=30) or the control group (n=30) after consenting to participate in the study. Participants in both groups will be asked to monitor their blood glucose for 5 days for the 28th, 32nd and 36th week of gestation. Primary outcomes to be evaluated include maternal A1c and offspring birth weight. To assess the feasibility and acceptability of CGMs among First Nations women, a questionnaire will be distributed to participants to gather insight into their rationale for enrolling into either group. Recruitment rates for both groups will also be used to assess feasibility and acceptability of CGMs. Additionally, all participants will be encouraged to participate in a community lifestyle program consisting of 30-min exercise sessions offered five days a week. The community lifestyle program will be adapted to the community, linked to existing programs with support from program personnel and will include educational sessions related to diabetes and healthy lifestyles. It is hypothesized that through participation in the community lifestyle program, pregnant First Nations women with diabetes will experience a decrease in their blood glucose values post-exercise, mitigate excessive weight gain and normalize their A1c's. It is further hypothesized that an increase in women's regular physical activity levels, the number of steps taken and knowledge of diabetes will be observed.

Interventions

DEVICEContinuous Glucose Monitoring

Participants in the CGM group will be asked to monitor their blood glucose for 5 days for the 28th, 32nd and 36th week of gestation using the iPro2 CGM.

Participants in the control group will be asked to monitor their blood glucose for 5 days for the 28th, 32nd and 36th week of gestation using a glucose meter.

Sponsors

Juvenile Diabetes Research Foundation
CollaboratorOTHER
Stewart Harris
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* First Nations (self-identified) * On-reserve (living or receiving care) * Informed consent to participate * Adults aged 18 years or older * Diagnosed with gestational diabetes (GDM) or type 2 diabetes (T2DM) * Pregnant (less than or equal to 36 weeks o gestation) * Consent to have primary care giver informed of participation in teh project * Willingness to perform required study and data collectin procedures and adhere to the operating requirements of the iPro2 and/or the glucose meter * Willingness to wear the iPro 2 continuous glucose monitor (CGM) for 5 days for the 28th, 32nd, 36th week of pregnancy (for participants in the CGM group) * Willingness to perform at least 4 finger prick testing per day during the Monitoring Week of the 28th, 32nd, 36th week of pregnancy (for CGM and control group)

Exclusion criteria

* Lack of decision making capacity to provide consent * Participating in another diabetes and/or lifestyle improvement research project * Non-First Nations descent * Pregnant diagnosed with type 1 diabetes * Pregnant not diagnosed with GDM or T2DM * Pregnant women past 36th week of gestation * Participants who do not consent to have their primary care giver informed of project participation * The participant has a history of tape allergies that have not been resolved * The participant has any skin abnormality (e.g. Psoriasis, rash, staphylococcus infection) that has not been resolved and would inhibit her from wearing the sensor * Any other condition (s) that in the Investigator's opinion would warrant exclusion from the study or prevent the participant from completing the project

Design outcomes

Primary

MeasureTime frameDescription
Maternal HbA1c24, 28, 32 and 36th week of gestation. This will occur between May 2012 to September 2014Lab collected at the specific time periods listed above.
Offspring Birth WeightAt Delivery. This will occur between May 2012 to September 2014.Offspring birth weight will be collected from the Neonatal Examination Form/Birth Record and Maternal and Offspring Discharge Summaries.

Secondary

MeasureTime frameDescription
Maternal diabetes treatment28, 32, and 36 weeks of gestation. This will occur between May 2012 to September 2014.Baseline treatment will be collected from Antenatal Record 1 and 2 (Ontario Ministry of Health and Long-Term Care forms) if available.
Daily mean glucose values (maternal)28, 32 and 36th week of gestation. This will occur between May 2012 to September 2014.This will be calculated from the glucose measurements taken using either the CGM or the glucose meter.
Insulin Use (maternal)24, 28, 32, and 36 weeks of gestation. This will occur between May 2012 to September 2014.Baseline insulin use will be collected from Antenatal Record 1 and 2 (Ontario Ministry of Health and Long-Term Care forms) if available.
Neonatal gestational ageAt Delivery. This will occur between May 2012 to September 2014.Neonatal gestational age will be collected from the Neonatal Examination Form/Birth Record and Maternal and Offspring Discharge Summaries.
Neonatal hypoglycemiaAt Delivery. This will occur between May 2012 to September 2013.Neonatal hypoglycemia will be collected from the Neonatal Examination Form/Birth Record and Maternal and Offspring Discharge Summaries.
Neonatal Intensive Care Unit (NICU) AdmissionAt Delivery. This will occur between May 2012 to September 2014.This will be collected from the Neonatal Examination Form/Birth Record and Maternal and Offspring Discharge Summaries.
Number of days in the hospital (neonatal)At Delivery. This will occur between May 2012 to September 2014.This will be collected from the Neonatal Examination Form/Birth Record and Maternal and Offspring Discharge Summaries.
1 hour post-prandial glucose measurements (maternal)28, 32 and 36th week of gestation. This will occur between May 2012 to September 2014.This will be collected from the CGM or glucose meter, depending on the group the participant consents to take part in.
Jaundice (neonatal)At Delivery. This will occur between May 2012 to September 2014.This will be collected from the Neonatal Examination Form/Birth Record and Maternal and Offspring Discharge Summaries.
Delivery in a community or teaching hospitalAt Delivery. This will occur between May 2012 to September 2014.This will be collected from the Neonatal Examination Form/Birth Record and Maternal and Offspring Discharge Summaries.
Caesarean section rate (maternal)At Delivery. This will occur between May 2012 to September 2014.This will be collected from the Neonatal Examination Form/Birth Record and Maternal Discharge Summary.
Delivery MethodsAt Delivery. This will occur between May 2012 to September 2014.Forceps, vacuum-assisted. This will be collected from the Neonatal Examination Form/Birth Record and Maternal and Offspring Discharge Summaries.
Cephalopelvic disproportionAt Delivery. This will occur between May 2012 to September 2014.This will be collected from the Neonatal Examination Form/Birth Record and Maternal and Offspring Discharge Summaries.
Number of days in hospital post delivery (maternal)At Delivery. This will occur between May 2012 to September 2014.This will be collected from the Maternal Discharge Summary.
Shoulder Dystocia (neonatal)At Delivery. This will occur between May 2012 to September 2014.This will be collected from the Neonatal Examination Form/Birth Record and Maternal and Offspring Discharge Summaries.
Birth injuries (neonatal)At Delivery. This will occur between May 2012 to September 2014.This will be collected from the Neonatal Examination Form/Birth Record and Maternal and Offspring Discharge Summaries.
Weight gain (maternal)Weight is recorded at each visit from May 2012 to September 2014.Baseline weight is collected from Antenatal Record 1 and 2 (Ontario Ministry of Health and Long-Term Care forms). Follow-up weight measurements are done at each visit until delivery. Weight gain is calculated from the baseline and follow-up measurements.

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026